New pill shows promise against tough prostate cancer
NCT ID NCT07218666
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 4 times
Summary
This study tests a daily pill called zanzalintinib in 30 men with aggressive variant prostate cancer that has spread. The goal is to see if the drug can slow or stop cancer growth. Participants take the pill once a day and are monitored for side effects and how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE VARIANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert and The Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.